Skip to main content

Share story

Security

Gyazo breach exposed metadata for 490 million images

Gyazo breach exposed metadata for 490 million images Image: Primary
A breach at screenshot-sharing service Gyazo exposed nearly 24 million customer records and an additional 490 million image-metadata records, Infosecurity Magazine reported. Attackers exploited an upload-server vulnerability, gaining data that included image IDs, source IP addresses, location information, extracted text, source URLs and hashed passphrases. Developer Helpfeel said some metadata could be used to construct image URLs and view corresponding images without authorization, prompting it to disable access to some images temporarily. The company remediated the vulnerability and urged password changes. Much of the affected image data dates from January 2019 or earlier, reducing the usefulness of some exposed credentials.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Infosecurity Magazine and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...